MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000)

Journal of Veterinary Internal Medicine

Volumn 16, Issue 5, 2002, Pages 576-580

  Rassnick, Kenneth M ^a,e   Mauldin, Glenna E ^b   Al Sarraf, Renee ^c,f   Mauldin, G Neal ^b   Moore, Antony S ^a   Mooney, Samantha C ^d,g  

^a TUFTS UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c Veterinary Referral Center   (United States)

^d ANIMAL MEDICAL CENTER   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f Veterinary Cancer Services   (United States)

^g DMS Laboratories   (United States)

Author keywords

Canine; Lymphosarcoma; Rescue

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; MOPP PROTOCOL; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG RESISTANCE; FEMALE; LYMPHOMA; MALE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; FEMALE; LYMPHOMA; MALE; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 0041737061     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2002.tb02390.x     Document Type: Article

References (26)

1. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease J Clin Oncol 1986;4:1295-1306.
2. Gobbi PG, Cavalli C. Rossi A, et al. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients. Haematologica 1987;72:523-528.
3. Hancock BW, Vaughan HG, Vaughan HB, et al. British National Lymphoma Investigation randomised study of MOPP (mustine, oncovin, procarbazine. prednisolone) against LOPP (leukeran substituted for mustine) in advanced Hodgkin's disease - Long term results. Br J Cancer 1991;63:579-582.
4. Coiffier B. Treatment of aggressive non-Hodgkin's lymphoma. Semin Oncol 1999;26(5 Suppl 14): 12-20.
5. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin's lymphoma: Standard and experimental approaches. Semin Hematol 1999;36:282-289.
6. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321.
7. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
8. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet Intern Med 1993;7:289-295
9. Price GS, Page RL, Fischer BM, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991;5:259-262.
10. Carter RE Harris CK, Withrow SJ, et al Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicm alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587-596.
11. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
12. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. J Am Anim Hosp Assoc 2000;36:404-409.
13. Piek CJ, Rutteman GR, Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Vet Q 1999;21:44-49.
14. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
15. Lucroy MD, Phillips BS, Kraegel SA, et al. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 1998;12:325-329.
16. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
17. Hammer AS, Couto CG, Ayl RD, Shank KA. Treatment of tumor-bearing dogs with actinomycin D. J Vet Intern Med 1994;8:236-239.
18. VanVechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187-191.
19. Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organization; 1980:21-25.
20. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475-479.
21. Bergman PJ, Ogilvie GK. Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein Sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996;10:354-359.
22. Lee JJ, Hughes CS, Fine RL. Page RL. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996;77:1892-1898.
23. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33.533-541.
24. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992;31:205-213.
25. Tew K, Coluin M, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, ed. Cancer Chemotherapy and Biotherapy. Philadelphia, PA: Lippincott-Raven; 1996:297-332
26. Hahn KA, Barnhill MA, Freeman KP, Shoieb AM. Detection and clinical significance of plasma glutathione-S-transferases in dogs with lymphoma. In Vivo 1999;13:173-175.